# Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies

> **NCT03328494** · PHASE1 · COMPLETED · sponsor: **Boston Pharmaceuticals** · enrollment: 38 (actual)

## Conditions studied

- Advanced Nonhaematologic Malignancies

## Interventions

- **DRUG:** BOS172722
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03328494
- **Lead sponsor:** Boston Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-13
- **Primary completion:** 2021-03-16
- **Final completion:** 2021-03-16
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2021-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03328494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03328494, "Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03328494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*